FDA Exploring NSAIDs Versus COX-2s; Advisory Meeting Planned In 2005
This article was originally published in The Tan Sheet
Executive Summary
FDA says it still lacks definitive evidence as to whether COX-2 selective agents have a different cardiovascular risk profile than traditional NSAIDs
You may also be interested in...
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting